CIRM Funded Clinical Trials

Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma

Disease Area: Multiple Myeloma
Investigator: Matthew Spear
Institution: Poseida Therapeutics, Inc.
CIRM Grant: CLIN2-10395
Award Value: $19,813,407
Trial Sponsor: Poseida Therapeutics, Inc.
Trial Stage: Phase 1
Trial Status: Active, not recruiting
Targeted Enrollment: 220
ClinicalTrials.gov ID: NCT03288493

Details:
Poseida Therapeutics is testing the safety of a gene modified cell therapy to treat multiple myeloma, the abnormal growth of malignant plasma cells of the immune system. The company’s technology is seeking to destroy these cancerous myeloma cells with an immunotherapy approach that uses the patient’s own engineered immune system T cells to seek and destroy the myeloma cells.

Design:
This is a Phase 1, open-label, multi-center study.

Goal:
Safety and Efficacy.

News about this clinical trial:
Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma
Poseida Raises $30.5 Million in Series B Financing

Contact Trial Sponsor

Source URL: https://www.cirm.ca.gov/clinical-trial/clinical-study-t-stem-cell-memory-tscm-based-car-t-cells-patients-multiple-myeloma